Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs

This article was originally published in The Pink Sheet Daily

Executive Summary

Probe launched by the Senate Aging panel asks four manufacturers – Valeant, Turing, Retrophin and Rodelis – for documents pertaining to pricing their products, but also wants to know how they may have analyzed FDA regs to help them avoid competition.

You may also be interested in...

Valeant Discounts Will Save Health Care System $600M Annually, Firm Says

In a direct distribution agreement with Walgreens, Valeant, often the focus of criticism over high drug prices, will cut prices 10% on branded dermatology and ophthalmology products and an average of over 50% on certain branded products with generic competition.

FDA Priority Review For Some Generics Urged To Address 'Market Failure'

Senate Aging Committee hearing addresses generic drug priority reviews at FDA, compounding and publicizing a “watch list” of off-patent drugs with no competition as ways of deterring dramatic price increases for such products.

Mylan Joins Firms Facing DOJ Probe On Price Hikes; Senate Plans Industry-Free Hearing

Senate Special Aging Committee hearing Wednesday to focus on price spikes in off-patent drugs without testimony from drug makers.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts